Combination therapy of cyclosporine and anti-tumor necrosis factor α in psoriasis: A case series of 10 patients

Dermatologic Therapy

Volumn 28, Issue 3, 2015, Pages 126-130

  Barak, Eran Cohen ^a   Kerner, Miryam ^a   Rozenman, Dganit ^a   Ziv, Michael ^a  

^a HAEMEK MEDICAL CENTER   (Israel)

Author keywords

anti TNF ; combination therapy; cyclosporine; psoriasis

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; ETRETIN; METHOTREXATE; TOPICAL AGENT; BIOLOGICAL PRODUCT; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CASE STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHRODERMA; FEMALE; GRAFT REJECTION; HEPATITIS C VIRUS; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NEPHROLOGIST; PHOTOTHERAPY; PSORIASIS; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; PUSTULOSIS; RETROSPECTIVE STUDY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS CARRIER; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DRUG EFFECTS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; REMISSION; SKIN; TIME FACTOR; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; BIOLOGICAL PRODUCTS; CYCLOSPORINE; DRUG THERAPY, COMBINATION; ETANERCEPT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SKIN; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84930762449     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/dth.12196     Document Type: Article

References (13)

1. Lucka TC, Pathirana D, Sammain A, et al. Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. J Eur Acad Dermatol Venereol 2012: 26: 1331-1344.
2. Amor KT, Ryan C, Menter A,. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol 2010: 63: 925-946.
3. Marqueling AL, Cordoro KM,. Systemic treatments for severe pediatric psoriasis: a practical approach. Dermatol Clin 2013: 31: 267-288.
4. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Amer Acad Dermatol 2008: 58: 826-850.
5. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP,. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013: 72: 517-524.
6. Mrowietz U, de Jong EM, Kragballe K, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2014: 28 (4): 438-453.
7. Lee EJ, Shin MK, Kim NI,. A clinical trial of combination therapy with etanercept and low dose cyclosporine for the treatment of refractory psoriasis. Ann Dermatol 2010: 22: 138-142.
8. Philipp S, Wilsmann-Theis D, Weyergraf A, et al. Combination of adalimumab with traditional systemic antipsoriatic drugs-a report of 39 cases. J Dtsch Dermatol Ges 2012: 10: 821-837.
9. Vine K, Votava HJ, Smith BL,. Generalized pustular psoriasis of Zambusch: case report of successful disease control with cyclosporine and etanercept. Cutis 2012: 90: 132-136.
10. Ricotti C, Kerdel FA,. Subacute annular generalized pustular psoriasis treated with etanercept and cyclosporine combination. J Drugs Dermatol 2007: 6: 738-740.
11. D'Angelo S, Cutro MS, Lubrano E, et al. Combination therapy with cyclosporin and etanercept in patients with psoriatic arthritis. Ann Rheum Dis 2010: 69: 934-935.
12. Karanikolas GN, Koukli EM, Katsalira A, et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol 2011: 38: 2466-2474.
13. Atzeni F, Boccassini L, Antivalle M, Salaffi F, Sarzi-Puttini P,. Etanercept plus cyclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. Ann Rheum Dis 2011: 70: 712-714.